FAQs

  • Q:

    What is the focus of the research?

    Show answer
    A:

    The primary outcome of a successful program is treatment development. The four priorities that will enable us to achieve this outcome are: • Understand and test progression so we can identify and test treatments • Design shorter, faster trials that measure patient outcomes • Conduct trials to test agents • Develop and evaluate new therapies to manage symptoms.

  • Q:

    Why have these four priorities been set?

    Show answer
    A:

    These priorities are the most significant barriers to develop treatments for progressive MS. As such, removing these four barriers are critical.

  • Q:

    Who sets the priorities?

    Show answer
    A:

    The Alliance’s Scientific Steering Committee sets the priorities and direction for its scientific program, which are then approved by the Executive Committee.

  • Q:

    This is focused on treatment – what about prevention, diagnosis, prognosis?

    Show answer
    A:

    By developing knowledge and understanding progression for identifying and testing new treatments, answers to these questions may be accelerated through the work of other Alliance members. Removal of the current barriers will complement, inspire, and fuel progress across the field of progressive MS.

  • Q:

    What do you hope to achieve and by when?

    Show answer
    A:

    The first grants will be awarded by August 2014 and we expect that programs funded through the Alliance will operate to 2019. By the end of 2016 the Alliance aims to be reviewing innovations funded through the Challenge Awards and starting to work with the most promising research institutions that will achieve our four objectives. By 2019 we expect agents to be tested in Food and Drug Administration- and European Medicines Agency-approved clinical trials, designed and funded by the Alliance. Ultimately we hope to realize the development of new treatments for progressive MS.

  • Q:

    Who will conduct the research?

    Show answer
    A:

    Research will be carried out by the individuals and institutions that submit the best applications. We will fund the best science with the clearest links to the Alliance’s objectives, wherever this is in the world.

  • Q:

    How global is the Alliance?

    Show answer
    A:

    Alliance members include the MS organisations of Australia, Belgium, Canada, Denmark, Germany, Italy, the Netherlands, Spain, USA and the UK as well as the MS International Federation. The Alliance invites membership from all organisations from the global MS community. The Alliance’s Scientific Review Committees include many of the leading MS scientists from around the world. This level of international participation and collaboration is unprecedented in the history of MS research and is one of the unique appeals of the Alliance. In the first request for applications, the Alliance received 195 applications from 21 countries.

  • Q:

    Who will decide which applications will be funded?

    Show answer
    A:

    The Alliance’s Scientific Review Committees will identify which projects have the highest scientific merit and alignment with the Alliance’s priorities through a rigorous peer review process. The Scientific Steering Committee will oversee this process and recommend projects for funding to the Executive Committee.

If you have a question for the Progressive MS Alliance, please contact us.

Sign up to our e-newsletter
for updates from our growing global initiative to end progressive MS